Literature DB >> 21330841

Risk factors for persistent low bladder compliance after radical hysterectomy.

Yasunari Oda1, Yukiharu Todo, Sharon Hanley, Masayoshi Hosaka, Mahito Takeda, Hidemichi Watari, Masanori Kaneuchi, Masataka Kudo, Noriaki Sakuragi.   

Abstract

INTRODUCTION: Bladder compliance deteriorates immediately after radical hysterectomy (RH), and low bladder compliance causes upper urinary tract dysfunctions such as progressive hydronephrosis. The aims of this study were to clarify risk factors for persistent low bladder compliance after RH and to propose a postsurgical management protocol for improved recovery of bladder function.
METHODS: A total of 113 consecutive patients who underwent RH with the intention to preserve the pelvic autonomic nerve system were included in this prospective study. Urodynamic studies were performed according to a planned schedule: presurgery and 1, 3, 6, and 12 months after surgery. Autonomic nerves were preserved at least unilaterally in 95 (84.1%) of the 113 patients, but this was not possible in the remaining 18 patients (15.9%). Postoperative adjuvant radiation therapy (RT) was performed in 14 patients. The relationships between bladder compliance and various clinical factors were investigated using logistic regression analysis. Covariates included age, nerve-sparing procedure, adjuvant RT, and maximum abdominal pressure during the voiding phase. Bladder compliance at 12 months after surgery was used as the dependent variable.
RESULTS: Radical hysterectomy with a non-nerve-sparing procedure (odds ratio [OR], 3.4; 95% confidence interval [CI], 1.1-11.0), adjuvant RT (OR, 10.3; 95% CI, 2.5-43.5), and voiding with abdominal pressure at 3 months after surgery (OR, 2.9; 95% CI, 1.1-7.2) were risk factors for persistent low bladder compliance.
CONCLUSIONS: A nerve-sparing procedure and prohibition of voiding with abdominal strain during the acute and subacute phases after RH resulted in improved recovery of bladder compliance. Adjuvant RT should be avoided in patients who undergo nerve-sparing RH if an alternative postoperative strategy is possible.

Entities:  

Mesh:

Year:  2011        PMID: 21330841     DOI: 10.1097/IGC.0b013e318204c3df

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  8 in total

Review 1.  Cervical cancer survivorship: long-term quality of life and social support.

Authors:  Krista S Pfaendler; Lari Wenzel; Mindy B Mechanic; Kristine R Penner
Journal:  Clin Ther       Date:  2015-01-01       Impact factor: 3.393

Review 2.  Urological complications after treatment of cervical cancer.

Authors:  Esther M K Wit; Simon Horenblas
Journal:  Nat Rev Urol       Date:  2014-01-28       Impact factor: 14.432

Review 3.  Management of Lower Urinary Tract Symptoms After Pelvic Radiation in Females.

Authors:  Laura S Leddy
Journal:  Curr Urol Rep       Date:  2018-10-31       Impact factor: 3.092

4.  Urodynamic study of bladder function following nerve sparing radical hysterectomy.

Authors:  Francesco Maneschi
Journal:  J Gynecol Oncol       Date:  2014-07       Impact factor: 4.401

Review 5.  Lower urinary tract dysfunction in pelvic gynecologic cancer: the role of urodynamics.

Authors:  Fouad Aoun; Alexandre Peltier; Roland van Velthoven
Journal:  Adv Urol       Date:  2014-11-23

6.  Adjuvant chemotherapy for early-stage cervical cancer.

Authors:  Hiroshi Asano; Yukiharu Todo; Hidemichi Watari
Journal:  Chin J Cancer Res       Date:  2016-04       Impact factor: 5.087

7.  Urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy.

Authors:  Satoshi Tsunetoh; Yoshito Terai; Masaaki Takai; Satoe Fujiwara; Yoshimichi Tanaka; Tomohito Tanaka; Hiroshi Sasaki; Naokazu Ibuki; Takanobu Ubai; Kazuhiro Yamamoto; Haruhito Azuma; Masahide Ohmichi
Journal:  Oncotarget       Date:  2019-08-27

Review 8.  Nerve-sparing radical hysterectomy in the precision surgery for cervical cancer.

Authors:  Noriaki Sakuragi; Gen Murakami; Yosuke Konno; Masanori Kaneuchi; Hidemichi Watari
Journal:  J Gynecol Oncol       Date:  2020-01-21       Impact factor: 4.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.